Nerandomilast, a Preferential Phosphodiesterase 4B Inhibitor, Dampens T-Cell Activation and Effector Function (ACR Convergence 2026) - Sep 8, 2026 - Abstract #972; Pres time: Nov 9, 2026; 10:30 AM - 12:30 PM; Location: WB1&2; In Person; "Our findings demonstrate that nerandomilast broadly attenuates T-cell activation and effector function in response to TCR activation. These results provide mechanistic evidence supporting preferential PDE4B inhibition as a promising therapeutic strategy in autoimmune diseases driven by aberrant T-cell activation, such as lupus, systemic sclerosis and myositis."
IO biomarker • Fibrosis • Immunology • Inflammation • Inflammatory Arthritis • Lupus • Myositis • Respiratory Diseases • Scleroderma • Systemic Sclerosis • CD4 • CD69 • CD8 • GZMB • IFNG • IL2RA
|
|
Sarah-Anne Nicholas1; Daniela Schloesser1; Peter Nickolaus2; Jochen Schmitz1; Karim Christian El Kasmi1
|